I am a PhD Candidate with focus on sensory neuropharmacology at the Centre for Pain Research at the Institute for Molecular Bioscience, The University of Queensland, Australia. Prior to my PhD studies, I completed a vocational training at a technical college in Germany to become a technical laboratory assistant with a focus on bioinformatics and molecular biology, which was followed by a degree in Pharmacy from the University of Tuebingen, Germany. Thereafter, I gained research experience in pharmacology and pain research as an occupational trainee at the Institute for Molecular Bioscience, The University of Queensland, and as a Research Assistant at the Clinic for Anesthesiology, University of Erlangen-Nuremberg, Germany. My current research focusses on chemotherapy induced neuropathic pain. Neuropathic pain is one of the most undertreated pain conditions in the world, mostly due to a lack of effective treatment and limited knowledge about the mechanism of its development. I am combining sophisticated behavioral assessment techniques such as electronical von Frey, Hargreaves, Catwalk XT and Behavioral Spectrometer measurements with calcium imaging, cytology, histology, immunohistochemistry, transcriptomics and proteomics to discover novel therapeutic targets for the treatment of chemotherapy induced pain as well as to understand the mechanism of its development. Additionally, I am interested in the kinetic properties of alpha7 nicotinic acetylcholine-receptor, the involvement of the Transient receptor potential channel 5 in cold sensing, and the voltage-gated sodium channel α-subunit 7 as a pain target, using electrophysiology and the high throughput imaging platform FLIPRtetra. My past research addressed the discovery of hereditable traits that cause differential development of neuropathic symptoms after oxaliplatin administration using haplotype based computational genetic